NASDAQ:LGND - Nasdaq - US53220K5048 - Common Stock - Currency: USD
102.19
+1.28 (+1.27%)
The current stock price of LGND is 102.19 USD. In the past month the price decreased by -6.38%. In the past year, price increased by 20.15%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 53.61 | 699.12B | ||
JNJ | JOHNSON & JOHNSON | 15.44 | 373.45B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 20.03 | 317.70B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.93 | 228.64B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 16.55 | 225.80B | ||
MRK | MERCK & CO. INC. | 9.86 | 192.95B | ||
PFE | PFIZER INC | 7.32 | 133.55B | ||
SNY | SANOFI-ADR | 11.17 | 120.15B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.58 | 98.25B | ||
GSK | GSK PLC-SPON ADR | 9.26 | 83.23B | ||
ZTS | ZOETIS INC | 28.01 | 75.08B | ||
HLN | HALEON PLC-ADR | 23.16 | 51.10B |
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. The company is headquartered in San Diego, California and currently employs 68 full-time employees. The company does this by financing, licensing its technologies or both. The company operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. The company has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
LIGAND PHARMACEUTICALS
3911 Sorrento Valley Blvd, Suite 110
San Diego CALIFORNIA 92121 US
CEO: John L. Higgins
Employees: 68
Phone: 18585507500
The current stock price of LGND is 102.19 USD. The price increased by 1.27% in the last trading session.
The exchange symbol of LIGAND PHARMACEUTICALS is LGND and it is listed on the Nasdaq exchange.
LGND stock is listed on the Nasdaq exchange.
13 analysts have analysed LGND and the average price target is 146.37 USD. This implies a price increase of 43.23% is expected in the next year compared to the current price of 102.19. Check the LIGAND PHARMACEUTICALS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
LIGAND PHARMACEUTICALS (LGND) has a market capitalization of 1.97B USD. This makes LGND a Small Cap stock.
LIGAND PHARMACEUTICALS (LGND) currently has 68 employees.
LIGAND PHARMACEUTICALS (LGND) has a support level at 99.57 and a resistance level at 102.5. Check the full technical report for a detailed analysis of LGND support and resistance levels.
The Revenue of LIGAND PHARMACEUTICALS (LGND) is expected to grow by 18.06% in the next year. Check the estimates tab for more information on the LGND EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LGND does not pay a dividend.
LIGAND PHARMACEUTICALS (LGND) will report earnings on 2025-08-04, after the market close.
The PE ratio for LIGAND PHARMACEUTICALS (LGND) is 17.5. This is based on the reported non-GAAP earnings per share of 5.84 and the current share price of 102.19 USD. Check the full fundamental report for a full analysis of the valuation metrics for LGND.
The outstanding short interest for LIGAND PHARMACEUTICALS (LGND) is 6.48% of its float. Check the ownership tab for more information on the LGND short interest.
ChartMill assigns a technical rating of 1 / 10 to LGND. When comparing the yearly performance of all stocks, LGND turns out to be only a medium performer in the overall market: it outperformed 58.11% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to LGND. While LGND has a great health rating, its profitability is only average at the moment.
Over the last trailing twelve months LGND reported a non-GAAP Earnings per Share(EPS) of 5.84. The EPS increased by 16.33% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -14.6% | ||
ROE | -16.6% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 85% to LGND. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 9.09% and a revenue growth 18.06% for LGND